AXA Framlington Biotech R Acc USD
Latest (Mid) Price:
USX 168.20
Day Change:
+0.15%
| Shares Class | Inc. |
|---|---|
| Yield | 0.00 |
| Total Expense Ratio | 0.00 |
Fund Performance
Cumulative Performance
Discrete Performance
MoneyAM Fund Centre
Quick Stats
| Fund Size | 516,681,500.00 | Launch Date | 02/11/2001 | Standard Initial Charge (%) | 0.00 |
|---|---|---|---|---|---|
| Currency | USX | ISA Eligible | Yes | Annual Management Charge (%) | 1.75 |
| Sector | IMA UK Equity Income | Min Investment (£) | 1,000.00 | Total Expense Ratio (%) | 0.00 |
| ISIN | GB00BZ3T0190 | Min Topup (£) | 100.00 | Ongoing Charge (%) | 1.8200 (on 13/03/2020) |
Fund Objective
The aim of this Fund is to provide long-term capital growth.
Fund Managers
Linden Thomson
Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.
Peter Hughes
Asset Breakdown
| Name | Weight |
|---|---|
| Europe ex UK Equities | 7.00% |
| Global Emerging Market Equitie | 3.00% |
| Money Market | 3.00% |
| North American Equities | 81.00% |
| UK Equities | 3.00% |
Region Breakdown
| Name | Weight |
|---|---|
| Europe ex UK | 7.00% |
| Global Emerging Markets | 3.00% |
| Money Market | 3.00% |
| North America | 81.00% |
| UK | 3.00% |
Sector Breakdown
| Name | Weight |
|---|---|
| Biotechnology/Medical | 84.00% |
| Money Market | 3.00% |
| Pharmaceuticals | 1.00% |
| Technology | 4.00% |
Top 10 Holdings
| Name | Weight |
|---|---|
| ALEXION PHARMACEUTICALS INC | 6.00% |
| AMGEN INC | 6.00% |
| REGENERON PHARMACEUTICALS INC | 5.00% |
| VERTEX PHARMACEUTICALS INC | 4.00% |
| BIOGEN INC | 3.00% |
| GILEAD SCIENCES INC | 3.00% |
| SEATTLE GENETICS INC | 3.00% |
| BIOMARIN PHARMACEUTICAL | 2.00% |
| ILLUMINA INC | 2.00% |
| INCYTE CORP | 2.00% |
Please remember that past performance is not a guide of future returns. The value of investments and the income from them can go down as well as up as a result of currency exchange and market fluctuations and investors may not get back the amount originally invested.
Fund data supplied by
